Inhibition of RAD51 led to the accumulation of DNA damage and enhanced drug efficacy in drug-naïve, vemurafenib-resistant and vemurafenib and trametinib double-resistant melanoma cells, as well as in a xenograft of melanoma cells isolated from a patient with developed resistance to vemurafenib [33]. Here, RAD51 is linked to melanoma.